Single-Nucleotide-Specific Lipidic Nanoflares for Precise and Visible Detection of KRAS Mutations via

Chan Li1, Haiyan Jia1, Xiaoling Wei1

  • 1Wenzhou Key Laboratory of Cancer Pathogenesis and Translation, Key Laboratory of Laboratory Medicine, Ministry of Education, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou 325000, PR China.

Analytical Chemistry
|March 4, 2024
PubMed

Insights

This study presents novel lipidic nanoflares for precise detection of circulating tumor DNA (ctDNA) mutations. The system accurately identifies single-nucleotide variations in ctDNA, crucial for cancer diagnostics and research.

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Nanotechnology

Background:

  • Accurate detection of circulating tumor DNA (ctDNA) single-nucleotide mutations is vital for cancer surveillance and research.
  • Low ctDNA expression and interference from homologous species present significant detection challenges.

Purpose of the Study:

  • To develop a single-nucleotide-specific method for precise and visible detection of ctDNA.
  • To overcome challenges in ctDNA detection in complex biological environments.

Main Methods:

  • Introduction of single-nucleotide-specific lipidic nanoflares assembled from cholesterol-conjugated multifunctional molecular beacons (MMBs).
  • Utilizing toehold-initiated self-priming DNA polymerization (TPP) for strand displacement and single-base discrimination.
  • Employing hydrophobicity-mediated aggregation for compact MMB arrangement on lipidic micelles.

Main Results:

  • Successfully detected KRAS G12D mutations in ctDNA against wild-type KRAS with high specificity.
  • Demonstrated robust signal transduction unaffected by coexisting homologous species.
  • Achieved a limit of detection as low as 10 amol, with visible fluorescence imaging of mutations.

Conclusions:

  • The developed lipidic nanoflare system enables precise, visible, and sensitive detection of ctDNA single-nucleotide mutations.
  • The system shows high potential for clinical diagnosis and personalized medicine, particularly in resolving KRAS gene mutations in colorectal cancer.